Delivery Order SPE2DR25D2104-SPE2DR26F3UQL
- Not listed
- The Defense Logistics Agency awarded a $1,038.10 delivery order to AmerisourceBergen Drug Corp on January 28, 2026, for the supply of Qulipta 60 mg tablets (30-count packaging). This firm fixed-price delivery order, with an ultimate completion date of January 29, 2026, represents a child contract under AmerisourceBergen's parent company Cencora, Inc. The award was made on a competitive, non-set-aside basis, with performance to be fulfilled at the company's Conshohocken, Pennsylvania location....
- The Defense Logistics Agency awarded a $3,899.68 delivery order to AmerisourceBergen Drug Corp on November 12, 2025, for the supply of Qulipta 60 mg tablets (quantity: 30 tablets). This is a firm fixed-price, competitively awarded contract with performance at the contractor's Conshohocken, Pennsylvania location and an ultimate completion date of November 13, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $12,962.72 to AmerisourceBergen Drug Corp for Qulipta 60 mg tablets (30-count units) on November 20, 2025, with an ultimate completion date of November 21, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $1,420.07 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Qulipta 60 mg tablets (30-count). This firm fixed-price, non-set-aside contract is scheduled for completion by July 21, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical....
- The Defense Logistics Agency awarded a delivery order valued at $4,996.39 to AmerisourceBergen Drug Corp for 30-tablet supplies of Qulipta 60 mg tablets. This is a firm fixed price, non-set-aside contract with an ultimate completion date of November 21, 2025, performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a purchase of pharmaceutical inventory under the company's existing contract vehicle with DLA. This delivery order is a child...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Qulipta 60 mg tablets in a quantity of 30 units, valued at $7,459.83. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and was awarded on July 29, 2025, with an ultimate completion date of July 30, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Qulipta 60 mg tablets (30-count) under a firm fixed-price contract valued at $10,801.96, with an ultimate completion date of September 8, 2025. This non-set-aside delivery order represents a competitive procurement of pharmaceutical products to support federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a...
- The Defense Logistics Agency awarded a $7,481.34 delivery order to AmerisourceBergen Drug Corp for Qulipta 60 mg tablets (30-count supply) on August 27, 2025, with an ultimate completion date of August 28, 2025. This firm fixed price contract represents a non-set-aside, competitively awarded delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The prime...
- The Defense Logistics Agency awarded a delivery order valued at $4,197.93 to AmerisourceBergen Drug Corp for Qulipta 60 mg tablets (30-count) on December 10, 2025, with completion scheduled for December 11, 2025. This firm fixed-price delivery order is not set-aside and represents a competitively awarded transaction under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $5,471.33 to supply Qulipta 60 mg tablets (30-count packages) for delivery to the company's Conshohocken, Pennsylvania headquarters. This competitively awarded, firm fixed-price contract was executed on June 17, 2025, with an ultimate completion date of June 18, 2025, and carries no set-aside designation. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DR25D2104Indefinite Delivery Contract
- SPE2DR25D2104-SPE2DR26F3UQLDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,281.80 to AmerisourceBergen Drug Corp for the supply of Qulipta 60 mg tablets (30-count) on January 29, 2026, with completion expected by January 30, 2026. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s significant Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2031, which serves as the primary vehicle for supplying comprehensive pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp functions as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA Medical Supply Chain. Qulipta (quillivant extended-release capsules) is a neurological and psychiatric medication used in federal healthcare settings, and this delivery order exemplifies the company's role in fulfilling specialized pharmaceutical requirements across multiple therapeutic domains. The contract's structure as a delivery order under a large-value IDC demonstrates DLA's streamlined procurement approach for managing pharmaceutical supply needs across military treatment facilities and other federal medical institutions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.3k | 1/28/26 |